Atticus Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Atticus Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-660	Closed	–	–	373
2020 Q4	$0	Hold	660	–	–	﹤0.01%	355
2020 Q3	$1K	Hold	660	–	–	﹤0.01%	313
2020 Q2	$2K	Hold	660	–	–	﹤0.01%	282
2020 Q1	$3K	Sell	660 -690	-51%	-$2.27K	﹤0.01%	269
2019 Q4	$4K	Buy	+1,350	New	+$3.51K	﹤0.01%	268

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Atticus Wealth Management's BMY.RT Position: Q1 2021 in Review

Atticus Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 660 shares.

Atticus Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $4K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Atticus Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Atticus Wealth Management sold 660 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Atticus Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Atticus Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Atticus Wealth Management's 13F filing for Q1 2021, filed 15 Apr 2021.